Sleep Medicine

3 · 20 / page

Ask MedXY AI

Latest news

Tag

newsAD109Aroxybutynin

AD109 (Aroxybutynin and Atomoxetine): A Promising Oral Therapy for Obstructive Sleep Apnea in PAP-Intolerant Patients

By MedXY|Jul 2, 2026

The SynAIRgy phase 3 trial demonstrated that the fixed-dose combination of aroxybutynin and atomoxetine (AD109) significantly reduces airway obstruction and improves oxygenation in obstructive sleep apnea patients unable to tolerate positiv

Beyond Monotherapy: Combined High-Intensity Circuit Training and Sleep Health Intervention Synergistically Enhances Sleep and Cardiometabolic Outcomes

newscardiometabolic health

Sleep Medicine

Latest news

AD109 (Aroxybutynin and Atomoxetine): A Promising Oral Therapy for Obstructive Sleep Apnea in PAP-Intolerant Patients

Beyond Monotherapy: Combined High-Intensity Circuit Training and Sleep Health Intervention Synergistically Enhances Sleep and Cardiometabolic Outcomes

Scalable Solutions for Sleep: Converging Evidence from a Nationwide RCT and Meta-Analysis Validates Digital CBT-I